Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Febuxostat, sold under the brand name Uloric among others, is a medication used long-term to treat gout due to high uric acid levels. It is generally recommended only for people who cannot take allopurinol. It is taken by mouth.
Read the full article on WikipediaChronic gout Clinical criteria: The condition must be either chronic gouty arthritis or chronic tophaceous gout, AND Patient must have a medical contraindication to allopurinol; OR Patient must have a documented history of allopurinol hypersensitivity syndrome; OR Patient must have an intolerance to allopurinol necessitating permanent treatment discontinuation.
“Febuxostat is a non-purine selective inhibitor of xanthine oxidase. It works by non-competitively blocking the molybdenum pterin center, which is the active site of xanthine oxidase. Xanthine oxidase is needed to oxidize successively hypoxanthine and xanthine to uric acid. Thus, febuxostat inhibits xanthine oxidase, thereby reducing production of uric acid. Febuxostat inhibits both the oxidized and the reduced forms of xanthine oxidase by virtue of its tight binding to the molybdenum pterin site.”
“~5–8 hours”
Working under the parallel aged-care framework? Aged-care equivalent →